|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:2012
gptkb:FDA
|
|
gptkbp:can_be_combined_with
|
gptkb:trastuzumab
|
|
gptkbp:capacity
|
420 mg
|
|
gptkbp:chemical_formula
|
C646 H1000 N178 O198 S4
|
|
gptkbp:clinical_trial
|
gptkb:APHINITY_trial
gptkb:CLEOPATRA_trial
gptkb:NEOSPHERE_trial
Phase III
PERJETA trial
PERUSE trial
|
|
gptkbp:clinical_use
|
adjuvant therapy
neoadjuvant therapy
metastatic breast cancer
|
|
gptkbp:contraindication
|
pregnancy
lactation
hypersensitivity to pertuzumab
|
|
gptkbp:developed_by
|
gptkb:Genentech
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pertuzumab
|
|
gptkbp:indication
|
gptkb:HER2-positive_breast_cancer
|
|
gptkbp:invention
|
2029
patented
|
|
gptkbp:is_a_guide_for
|
ASCO guidelines
NCCN guidelines
|
|
gptkbp:is_monitored_by
|
left ventricular ejection fraction
|
|
gptkbp:is_vulnerable_to
|
low
|
|
gptkbp:knockouts
|
high
|
|
gptkbp:lifespan
|
about 18 days
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:USA
gptkb:EU
|
|
gptkbp:mechanism_of_action
|
HER2 dimerization inhibition
|
|
gptkbp:patient_population
|
adult men
adult women
|
|
gptkbp:pharmacokinetics
|
linear
|
|
gptkbp:research
|
other cancers
|
|
gptkbp:research_focus
|
combination therapies
HER2-targeted therapies
|
|
gptkbp:route_of_administration
|
IV
|
|
gptkbp:safety_measures
|
ongoing
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
rash
infusion-related reactions
neutropenia
cardiac dysfunction
|
|
gptkbp:storage
|
2 to 8 ° C
|
|
gptkbp:targets
|
gptkb:HER2
|
|
gptkbp:trade
|
gptkb:Perjeta
|
|
gptkbp:treatment
|
with chemotherapy
with hormonal therapy
|
|
gptkbp:used_for
|
gptkb:Oncology
|
|
gptkbp:weight
|
148 k Da
|
|
gptkbp:bfsParent
|
gptkb:EMD_Serono
|
|
gptkbp:bfsLayer
|
5
|